RxSight price target raised to $64 from $54 at Stifel

Stifel analyst Thomas Stephan raised the firm’s price target on RxSight to $64 from $54 and keeps a Buy rating on the shares. Few new developments came with the company’s Q4 results, relative to strong preliminary results and the initial 2024 guidance from January, the analyst tells investors. With an overall visible pathway, the stock is well positioned to be a solid 2024 momentum move, the firm adds. While valuation tempers the firm’s near-to-intermediate term enthusiasm for more upside, the company continues to be one of Stifel’s favorite long-term stories in ophthalmology.